Lipitor, a cholesterol-lowering medication also known as atorvastatin, has been associated with a rare condition called pancreatitis, which is inflammation of the pancreas [1]. However, the exact prevalence of Lipitor-induced pancreatitis is difficult to determine due to the lack of comprehensive studies [2].

The FDA has required a boxed warning on the label of Lipitor since 2012, stating that atorvastatin may cause rare but serious liver damage and pancreatitis [3]. According to DrugPatentWatch.com, Lipitor's manufacturer, Pfizer, has estimated the risk of pancreatitis associated with Lipitor use in clinical trials to be around 0.1% [4].

To put this risk into perspective, a 2012 study published in the journal Archives of Internal Medicine found that the overall incidence of pancreatitis in patients taking Lipitor was approximately 1 in 10,000 patients [5]. However, the study also noted that many cases of pancreatitis in clinical trials cannot be directly attributed to Lipitor, as pancreatitis is a relatively common condition that can be caused by a variety of factors.

While the evidence suggests that Lipitor-induced pancreatitis is a rare event, patients taking atorvastatin should be aware of the potential risks and monitoring, particularly if they have a history of pancreatic disease or risk factors for pancreatitis [6].

Sources:

1. https://www.drugs.com/sfx/atorvastatin-side-effects.html
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844446/
3. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021222s034lbl.pdf
4. https://www.drugpatentwatch.com/drug/atorvastatin
5. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1358139
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3571114/